Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma

BACKGROUND: We aimed to assess whether the Response Evaluation Criteria in Solid Tumors (RECIST)-based objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS) could serve as surrogate endpoints for overall survival (OS) in immune-oncology (IO) trials of advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuan Fang, Wang, Yun, Zhou, Jie, Wei, Yi Cheng, Lin, Jun, Yin, Yi Xin, Chen, Guo Ming, Zhang, Fei Yang, Chen, Shi, Zhou, Zhi Wei, Chen, Ying Bo, Cong Nie, Run
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239497/
https://www.ncbi.nlm.nih.gov/pubmed/35837321
http://dx.doi.org/10.14740/wjon1481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239497/
https://www.ncbi.nlm.nih.gov/pubmed/35837321
http://dx.doi.org/10.14740/wjon1481

Ejemplares similares